Monte connects FDA-regulated and commercial B2B businesses with the trusted partners, services and opportunities they need.
Public enforcement data, updated as it publishes — this is the market I watch.
- →FDA, animal health: Neogen Corporation and Sciarra Aeromed each cited for CGMP and insanitary conditions, issued 09/23/2026
- →FDA, pharma: Bentley Laboratories cited for unapproved new drug, misbranding and CGMP, issued 09/17/2026
- →Commercial, capital: BioStem Technologies, Sunshine Biopharma and HCW Biologics each filed an S-1 registration on 10/02/2026
- →Commercial, digital health: VSee Health filed an S-1 registration on 10/01/2026
Sourced from FDA warning letters and SEC EDGAR filings, September to October 2026.
No deal to point at yet — so here’s exactly what I put in motion.
- Business in motion → trusted partner A warning letter, a recall, a new filing. When something moves, the clock starts, and I put a vetted partner or service in front of the company while it still has options.
- Provider → the businesses that need them If you serve regulated or growing B2B companies for a living, I bring you the ones at the moment they learn they need you.
Building in the open. I’m working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while I route my first introductions in this lane. My first closed match replaces this paragraph.
What I see in this market that outsiders miss.